HC Wainwright Analysts Lift Earnings Estimates for Inventiva S.A. (NASDAQ:IVA)

Inventiva S.A. (NASDAQ:IVA - Free Report) - Stock analysts at HC Wainwright increased their FY2025 earnings per share estimates for Inventiva in a research note issued to investors on Monday, April 1st. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($2.92) for the year, up from their previous forecast of ($2.95). HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Inventiva's current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Inventiva's FY2026 earnings at ($3.11) EPS and FY2027 earnings at ($2.67) EPS.

IVA has been the topic of a number of other reports. Lifesci Capital reaffirmed an "outperform" rating on shares of Inventiva in a research report on Friday, January 5th. Stifel Nicolaus lowered their price objective on Inventiva from $27.00 to $25.00 and set a "buy" rating for the company in a report on Friday, February 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $15.67.

Inventiva Trading Up 0.5 %

Shares of IVA traded up $0.02 during midday trading on Thursday, reaching $3.66. 26,111 shares of the company were exchanged, compared to its average volume of 37,088. The stock has a 50-day moving average price of $3.72 and a 200-day moving average price of $3.98. Inventiva has a 1-year low of $2.22 and a 1-year high of $5.05.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC raised its stake in Inventiva by 20.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 24,435 shares of the company's stock valued at $103,000 after purchasing an additional 4,155 shares during the period. Citigroup Inc. raised its stake in Inventiva by 91.7% during the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company's stock valued at $84,000 after purchasing an additional 11,000 shares during the period. Finally, Morgan Stanley raised its stake in Inventiva by 300.0% during the 4th quarter. Morgan Stanley now owns 6,000 shares of the company's stock valued at $27,000 after purchasing an additional 4,500 shares during the period. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.